Product Images Gabapentin

The text describes a graph (Figure 1) showing weekly mean pain scores (Observed Cases in ITT Population) for Study 1. The graph includes a 4-week dose titration period, a 4-week fixed dose period, and two treatment groups: Placebo and Gabapentin, 3600 mg/day. The values of the baseline, weeks 1 through 8, and the significance level (p<0.01) are presented.*

The text represents data from a study regarding mean pain scores. The study consists of a 3-week dose titration period and a 4-week fixed dose period. Gabapentin is used at two different doses and a placebo is also used. There is a graph showing weekly mean pain scores from baseline through week 7. The data suggests that gabapentin at both doses is statistically significant in reducing pain compared to the placebo.*

The text describes a figure named "Figure 3" that shows the percentage of patients who responded positively to treatment (with a reduction of at least 50% in pain score) in two controlled studies for PHN (postherpetic neuralgia), using two different doses of GBP (gabapentin) and a placebo (PBO). It also includes a note about statistical significance based on p-values.*

The text describes a figure showing the Responder Rate of Gabapentin at various daily doses in patients over 12 years of age with Partial Seizures. There are different studies shown in the figure, and the Responder Rate is expressed as a difference from Placebo.*